|
See related Sprycel film-coated tab information |
|
|
|
Manufacturer |
Bristol-Myers Squibb |
|
Distributor |
DKSH |
|
Contents |
Dasatinib |
|
Indications |
Treatment of adults w/ chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukemia w/ resistance or intolerance to prior therapy including imatinib. Treatment of adults w/ Philadelphia chromosome positive acute lymphoblastic leukemia w/ resistance or intolerance to prior therapy including imatinib. |
|
Dosage |
70 mg bid, 1 in the morning & 1 in the evening. |
|
Administration |
May be taken with or without food (Swallow whole, do not break/crush/cut.). |
|
Special Precautions |
Myelosuppression; monitor CBC regularly. May cause platelet dysfunction & hemorrhage; caution in patients taking anticoagulants or antiplatelet drugs. Fluid retention. QT prolongation esp in patients w/ hypokalemia or hypomagnesemia, congenital long QT syndrome, concomitant antiarrhythmics or QT-prolonging drugs & cumulative high-dose anthracycline therapy. Lactose intolerance. Hepatic impairment. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Fluid retention eg pleural effusion, GI & bleeding events. Pyrexia, febrile neutropenia, GI bleeding, pneumonia, thrombocytopenia, dyspnea, anemia, cardiac failure, diarrhea.
View ADR Monitoring Form |
|
Drug Interactions |
CYP3A4 inhibitors (eg ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase dasatinib plasma conc. CYP3A4 inducers (eg dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarb) & St. John's wort may decrease dasatinib plasma conc. Antacids, H2-blockers/proton-pump inhibitors (eg famotidine, omeprazole). CYP3A4 substrates (eg alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, ergot alkaloids) may have their plasma conc altered by dasatinib.
View more drug interactions with Sprycel |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Sprycel film-coated tablet |
|
Sprycel 20 mg x 60's |
|
Sprycel 50 mg x 60's |
|
Sprycel 70 mg x 60's |
|
|
|
Manufacturer: |
Bristol-Myers Squibb |
|
Distributor: |
DKSH |
|
 |
|
|
|
